Transcriptional targeting is an important aspect of developing gene therapy vectors in order to restrict transgene expression to selected target cells. One approach, when using retroviral vectors, is to replace viral transcriptional control elements within the long terminal repeat (LTR) with sequences imparting the desired specificity. We have developed such hybrid LTR retroviruses, incorporating sequences from each of the human promoters for flt-1, ICAM-2 and KDR, as part of our antivascular cancer gene therapy strategy targeting tumour endothelial cells. The chosen fragments were used to replace the enhancer or combined enhancer and proximal promoter regions of the viral LTR. All showed activity in primary human breast microvascular endothelial cells, with viruses incorporating ICAM-2 sequences exhibiting the greatest specificity versus nonendothelial cells in vitro and a marked alteration of specificity towards endothelial cells in a subcutaneous xenograft model in vivo. Moreover, our study documents the effect of enhancer and/or proximal promoter deletion on LTR activity and reports that differential dependence in different cell lines can give the false impression of specificity if experiments are not adequately controlled. This finding also has implications for other retroviral vector designs seeking to provide transcriptional specificity and for their safety with respect to prevention of gene activation at sites of proviral integration.
Introduction
Solid tumours are dependent on vascular support for growth and metastasis, and the induction of angiogenesis is a discrete component of the tumour phenotype. 1 Tumour blood vessels have become a popular therapeutic target due to their ease of accessibility, their sensitivity to damage and the dependence of many tumour cells on relatively few vascular endothelial cells. Many antiangiogenic agents have been shown to reduce tumour growth, [2] [3] [4] and some, such as the endogenous inhibitors angiostatin and endostatin, also cause tumour regression. 5, 6 Antivascular approaches, such as use of Combretastatin A4, 7 target the existing tumour vasculature rather than preventing its expansion. To this end, we are developing gene therapy strategies to target the endothelial cells that line the vasculature of solid tumours, using murine leukaemia virus (MLV)-based vectors. Endothelial cells are normally quiescent but become activated in tumours, 8 rendering them sensitive to infection, and we have demonstrated that herpes simplex virus thymidine kinase (TK) expression in tumour vasculature followed by the administration of the prodrug ganciclovir can significantly reduce the growth of tumour xenografts. 9 Multiple levels of vector specificity can be envisaged, such as the use of modified envelope proteins or the expression of a specific therapeutic product. In this study, we have focused on the introduction of endothelial cell-specific transcriptional control.
In the provirus, the retroviral genes are flanked by 600 bp viral long terminal repeats (LTRs), within which the unique 3 0 (U3) region houses the viral transcriptional control elements. During the viral lifecycle, U3 becomes copied from the 3 0 -end of the RNA genome to the 5 0 LTR in the provirus, where it directs RNA polII-dependent transcription. The many binding sites for different transcription factors tightly packed into U3 are thought to explain the lack of any marked cell specificity. 10, 11 The promoter contains CAAT and TATA boxes, and an enhancer element maps to a 75 bp direct repeat. The introduction of additional promoters into MLV vectors requires the balancing of effects on vector RNA transcription in the packaging cell, necessary for high titre, with specific transcription in the infected cell, giving high levels of transgene expression. Tissuespecific expression has been attempted through the use of an internal expression cassette between two wild-type LTRs, but the presence of both viral and heterologous promoters can result in transcriptional interference and poor efficiency of expression. 12 Strategies to circumvent promoter interference by weakening LTR activity in the transduced target cell have been attempted by deletion or substitution of 3 0 LTR sequences. 13, 14 Alternatively, by substituting regions within U3 of the 3 0 LTR, the retroviral lifecycle can be exploited so that a single transcription unit is functional in the packaging cells (from the wild-type 5 0 LTR) and a different one is active in the infected cells (following duplication of the substitution). An example of this is the use of sequences derived from the myeloproliferative sarcoma virus LTR to drive expression in embryonal or haematopoietic stem and embryonal carcinoma (EC) cells where MLV expression is restricted. 15, 16 A base change that creates a consensus binding site for Sp1 is responsible for the increased transcriptional activity in EC cells. 17 The substitution or addition of sequences has also been used to restrict transcription to specific target cells. While certain lymphoid-specific enhancers failed to modify expression, 18 the insertion of a muscle creatine kinase enhancer between, or replacing, the enhancer and proximal promoter in the 3 0 LTR has been used to direct expression to differentiated myogenic cells. 19, 20 Similarly, targeting to melanoma cells has been achieved by replacing the viral enhancer with the tyrosinase promoter or enhancer fragment. 21, 22 However, the levels of gene expression from the latter were relatively low, reflecting the weakness of the exogenous fragment relative to the viral enhancer. Replacement of the viral enhancer with an autoregulatory enhancer of GATA-1 has resulted in targeting of expression to cells of erythroid lineage, 23 and insertion of a silencer into the LTR has been used to target CD4-positive cells. 24 This laboratory has previously adopted such a hybrid LTR strategy using fragments from the human preproendothelin-1 (ppET-1) promoter to direct endothelialspecific transcription. 25, 26 Vector design considerations were to generate a single transcriptional unit in the target cell and to avoid the use of selectable markers that may modify performance and would be inappropriate for eventual clinical application. However, since there can be great heterogeneity in endothelial cells due to development, cellular context and proliferation, 27 it was not obvious that the choice of ppET-1 promoter was optimal. It was therefore necessary to investigate fragments from different promoters and to characterize them in the hybrid LTR context. In this study, new hybrid vectors were generated using transcription regulatory fragments from the human genes for flt-1, ICAM-2 and KDR, and their performance investigated both in vitro and in vivo.
Results

Determination of vector configurations for modifying LTR specificity
In this study, we sought to develop hybrid LTR vectors using a number of endothelial cell-specific promoter fragments. We first analysed the relative contributions to LTR function of the enhancer region and the portion of the promoter immediately upstream of the basal TATA box element (subsequently referred to as the proximal promoter region) (Figure 1a and b). Vectors with engineered LTRs lacking either or both of these regions were constructed and virus harvested from bulk populations of producer cells was assayed for the expression of the internal marker gene (Figure 2a ) and end point titre (Figure 2b ). Human cell lines of various origin were used, as well as a porcine aortic endothelial (PAE) cell line used in our previous studies as a positive control for endothelial cell activity. 25, 26 Expression in 293 cells showed relatively little dependence on the presence of the viral enhancer (three-fold) compared to the other cell lines (10-to 20-fold). The 293 and PAE cells showed the most marked dependence on the proximal promoter (40-fold compared to 5-to 10-fold). Combining the deletions gave very low activity in all cases. These data were well matched by the effect on titre of the various deletions, although reduction was generally less affected than was enzyme activity, 0 LTR is expanded to show the NheI, XbaI and SacI sites that delineate the viral enhancer (E), encompassing the 75 bp repeats, and the proximal promoter (P), that includes the basal CAAT box motif but stops short of the TATA box. Also shown is the NotI site used to insert modified versions into the parental plasmid. Vectors DE, DP and DEP, respectively, lack the enhancer, proximal promoter or both regions. The U3 region of the 3 0 LTR was manipulated, since during reverse transcription this becomes duplicated in the 5 0 LTR to control expression in the transduced target cell. (c) Vectors used later in this study in which the enhancer or both the enhancer and the proximal promoter were replaced were constructed by inserting PCR fragments in place of the 270 bp NheI/XbaI fragment (DE strategy) or the 390 bp NheI/SacI fragment (DEP strategy), respectively. Inserted fragment sizes were 770 bp (flt-1), 300 bp (ICAM-2, illustrated) or 740 bp (KDR).
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TB Richardson et al indicating that the wild-type LTR activity is significantly above any threshold for histochemical staining. This is particularly so for PAE cells, consistent with the relatively high LTR activity in these cells assessed by comparing enzyme activity to the number of histochemically positive cells (B0.8 pg/cell compared to 0.2-0.3 pg/cell for other cells). Southern blot analysis of the proviral copy number in infected cells showed that deletion of the enhancer did not affect transduction efficiency, while deletion of the proximal promoter gave a small (approximately two-fold) reduction (data not shown). The effect of the deletions can otherwise be attributed to reduced transcriptional activity. These data show that the residual weak expression due to the retained TATA box, cap site and any downstream promoter elements, present in the fully deleted vector (DEP), is independently augmented by the proximal promoter region and the enhancer. For the majority of cell lines tested, it is the enhancer rather than the proximal promoter that exercises the greatest influence on LTR activity. We previously inserted ppET-1 sequences in the DEP backbone and obtained endothelial cell specificity in a panel of human cell lines in vitro. 25 Insertion into the DE backbone was also successful both in vitro and in vivo, while use of the DP backbone removed the specificity for PAE over the nonendothelial TE671 cells. 26 This is consistent with the elevated activity of DP in the latter.
In summary, the data presented in Figure 2 and the experience with the ppET-1 hybrid vectors indicate that the viral enhancer is dominant over changes made to the specificity of the proximal promoter, but that the activity of the viral promoter can be influenced by changes to the enhancer. For our further studies, we therefore decided to adopt (i) the DEP backbone, inserting a new proximal promoter region aligned with the residual TATA box so as to create a hybrid promoter with a configuration similar to that from which it was obtained, or (ii) the DE backbone, placing the same cluster of transcription factor binding sites upstream of the viral promoter ( Figure 1c ).
Generation of hybrid LTR retroviral vectors
The human flt-1, KDR and ICAM-2 genes were chosen from which to derive transcription regulatory sequences for incorporation into retroviral vectors. Flt-1 and KDR, encoding receptors for VEGF, are upregulated in areas of neovascularization, and might therefore be expected to show specificity for endothelial cells proliferating in response to angiogenic signals within tumours. [28] [29] [30] ICAM-2 is widely expressed on endothelial cells, including tumour vasculature. 31 All have been subjected to some promoter characterization with regard to endothelial specificity, using transient transfection assays for flt-1 32 and KDR 33 or transgenic mice for ICAM-2.
34
Promoter fragments were amplified from genomic DNA such that cloning into the DEP backbone, immediately prior to the viral TATA box, would regenerate the original spacing relative to the TATA box or, for the ICAM-2 and KDR promoters lacking a TATA box, relative to the transcription start site (Figure 1c ). In the latter cases, the LTR TATA box is expected to substitute for the initiator element found in such promoters, as has been previously seen for the murine terminal deoxynucleotidyl transferase promoter. 35 These same fragments were alternatively inserted into the DE backbone. LTR hybrids were similarly created based on the human CEA and erbB2 genes as nonendothelial cell-specific controls.
A bulk population of producer cells was selected for each construct for an initial assessment of vector performance (data not shown). Proviral copy numbers for the DEP-based vectors were approximately two-fold lower than those of the unmodified or the DE-based vectors, consistent with the data for the LTR deletion vectors used above. For the enhancer replacement vectors, the titre relative to DE was elevated (1.5-fold) on PAE cells for flt-1, was comparable for ICAM-2 and erbB2, and was reduced for KDR and CEA, while all were reduced on TE671 cells. The erbB2 vector (but not CEA) showed 1.7-fold elevated titre relative to DE on erbB2-positive MDA-MB361 cells. These observations, although complicated by the high activity of the DE backbone in PAE cells (see Figure 2b) , suggested that the chosen promoter regions could regulate the viral promoter in an appropriate cell context. In the DEP backbone, all constructs showed elevated activity in PAE but not TE671 cells, indicating that PAE cells are of limited value for assessing specificity. As PAE cells are relatively unreliant on enhancer activity, it may be that introduction of further basal elements present in each of the proximal promoters is sufficient for this activity. 
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Analysis of hybrid LTR retroviruses
Stable producer cell clones were isolated in order to generate high-titre virus for assessing specificity. Those with the highest titre were identified by titration on PAE cells since these cells, for the reasons mentioned above, allow assay regardless of the LTR modification. Southern blot analysis of DNA from infected TE671 cells demonstrated that the provirus was intact and that the selected clones gave similar copy numbers to that of the control virus (Figure 3a) . Modifications engineered in the 3 0 LTR were similarly shown to have been duplicated to the 5 0 LTR of the integrated provirus, and transgene expression in infected cells was shown by 5 0 -RACE to initiate at the authentic viral cap site (data not shown). The latter demonstrates that the TATA box is the major determinant of the start site of transcription in both wildtype and hybrid LTRs, generating the same spliced transcriptional leader in each case.
A panel of human cell lines was analysed by RT-PCR for the expression of flt-1, ICAM-2 and KDR ( Figure 4) . A subset of these cells, including a preparation of primary breast endothelial cells (PBECs), was chosen in which to assess the transcriptional activity of the new constructs (Figure 3b and c). As noted above, titration data provide a good surrogate for enzyme activity (which could not be determined for the poorly infectable primary cells).
The performance of vectors with enhancer replacement in the DE backbone was compared to that of DE itself (Figure 3b ). It was evident that some modifications were dominant over the viral promoter, exerting either a positive or a negative influence in some cell targets. For example, the ICAM-2-modified vector activity was Titres were also normalized to the relative copy number determined in (a) above to remove variations due to vector production differences between producer cell clones. Data are the mean7s.e. for three independent viral harvests from the highest titre producer cell clones of each construct. Control virus titres were of the order of 10 6 CFU/ml for TE671, 10 5 CFU/ ml for 293, KS Y-1, HMEC-1 and EAhy926, and 10 3 CFU/ml for PBECs. Enhancer deletion reduced titre relative to the control by 10-to 20-fold for PBECs and the other cell lines used, with the exception of 293 (see Figure  2b) . The relatively poor infectivity of PBECs is the reason for the large error bars for this cell target. Statistical significance was determined using the t-test. For the data in (b), only the ICAM-2 vector showed significantly enhanced titre compared to DE in PBECs (P ¼ 0.02), while all vectors showed a highly significant decrease in TE671 and 293 cells (P ¼ 0.004 or less). The performance relative to DE (as plotted) for each vector was significantly greater in PBECs versus TE671 (P ¼ 0.03 or less), and that for the ICAM-2 vector was significantly enhanced in PBECs compared to all nonendothelial cell lines used (P ¼ 0.04 or less). For the data in (c), the relative titre of the ICAM-2 vector was significantly different for PBECs versus all the other cell lines (P ¼ 0.01 or less).
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TB Richardson et al significantly enhanced and reduced in PBECs and TE671, respectively. There was also some enhancement for HMEC-1. This profile of activity was consistent with that of the endogenous promoter activity in these cells (see Figure 4) . The flt-1 and KDR vectors were not enhanced in PBECs but were significantly reduced in the negative TE671 cells. The KDR vector showed least variation between target cells. The ICAM-2 vector showed the greatest discrimination, approximately 70-fold (P ¼ 0.02), between the most relevant primary cell target (PBEC) and the nonendothelial cell line TE671, achieving 20% of the wild-type activity in PBECs. Vectors based on the DEP backbone were similarly analysed, comparing to the activity of the control unmodified virus (Figure 3c ). Only the primary target cells showed significant activity. The ICAM-2 promotermodified vector was again the best, giving 40% of the activity of that due to the wild-type LTR. Specificity in comparison of PBECs and TE671 was approximately 75-fold (P ¼ 0.004). Comparison with DE indicates that the performance of the reconstituted ICAM-2 promoter in the LTR is of the order of 10-fold greater than that of the viral promoter in PBECs and 10-fold weaker in TE671, the combination of the two yielding the high specificity observed.
In vivo expression pattern for hybrid LTR viruses
The performance of each of the vectors was assessed in a tumour xenograft model in nude mice by subcutaneous coinjection of the human cell line KS Y-1 with irradiated producer cells. This model enables transduction of both tumour and stromal cells as the tumour is established and is useful for assessing changes to transcriptional control in vivo. 26 Irradiated producer cells continue to produce virus efficiently in vitro but are cleared in vivo by the time the tumours are established. For the control, b-galactosidase expression was widespread throughout the tumour but positive cells within the stroma with the morphology characteristic of endothelial cells were rare (Figure 5a ). For the modified viruses staining was much less, although the amount of transduction and profile of target cells would be expected to be similar to the control, indicating altered transcriptional activity. For the strategy using the DEP backbone, the flt-1 and ICAM-2, but not KDR, vectors showed expression in a few tumour and stromal cells, including endothelial cells. For the enhancer-replacement strategy, DE (Figure 5b ) and the KDR derivative showed very weak expression in pockets of tumour cells and the flt-1 vector gave staining of some vascular endothelial cells. However, the ICAM-2 vector showed expression in morphologically typical endothelial cells lining vessels and in relatively few tumour cells (Figure 5c) , showing a marked alteration in specificity compared with the control.
Discussion
One aspect of targeting antivascular gene therapy to tumours is to control the level of transgene expression. Analysis of human promoters characterized for endothelial-specific expression led to the identification of fragments from the promoters of flt-1, 32 ICAM-2 34 and KDR 33 as suitable for transcriptional targeting. We have developed hybrid LTR retroviruses incorporating sequences from each of these and assessed them in vitro, on a cell line panel, and in vivo, in a subcutaneous xenograft model. The chosen fragments were used to replace the enhancer or combined enhancer and proximal promoter regions of the viral LTR. All showed activity in the most relevant cells, the primary breast microvascular endothelial cells, with viruses incorporating ICAM-2 sequences exhibiting the greatest specificity versus nonendothelial cells. Vector performance in vivo for ICAM-2 (and, to a lesser extent, flt-1) also showed a marked alteration of specificity towards endothelial cells compared to the unmodified vector, particularly for the enhancer-replacement strategy. The overall number of expressing cells was promising given that few endothelial cells were transduced with the control vector and that the copy number of the ICAM-2 vector producer cell clone obtained was relatively low (0.4). Initial studies to determine backbone effects due to deletion of the viral enhancer and/or proximal promoter showed that these regions function independently to support expression by the core promoter. There was a small (B2-fold) reduction in titre due to deletion of the proximal promoter, potentially attributable to less-efficient producer cell transcript termination at the 3 0 LTR, but otherwise the effects were transcriptional within the transduced target cell. Different cell lines showed differential dependence on the enhancer and proximal promoter for control of expression, an important consideration when assessing the performance of constructs retaining either of these in order to avoid the false impression of specificity. The activity of hybrids based on the DEP strategy was unequivocally due to the inserted It is important to use an assay system appropriate for the eventual proposed clinical application. For this reason we used human promoter sequences and chose a panel of human cells, including a preparation of primary microvascular endothelial cells, in which to perform the initial assessment of specificity. This consideration also influenced our choice of vector design to omit selectable markers that would ultimately be inappropriate. We subsequently used a murine xenograft model since a preclinical model is prerequisite for the further development of therapeutic strategies. Although analysis in vitro and in vivo can give contrasting predictors of clinical behaviour (consider, for example, the strong performance of the ICAM-2 hybrid in the DEP backbone in the primary human microvascular cells compared to its poor performance in the xenograft), vectors that can perform in both contexts are advantageous.
It is possible that the approach we have taken would fail to recapitulate the expression profile of the genes from which the promoter sequences derive, for several reasons. Firstly, the constraint of fitting the fragments into our chosen hybrid LTR strategy results in the loss of regulatory sequences immediately adjacent to or downstream of the cap site (ie downstream of the TATA box, when present). Secondly, promoter fragments were selected with reference to published promoter analyses in transient transfection assays using cells of non-human origin, or according to usage in transgenic mice, in contrast to the integrated retroviral context and use of human cell targets. An additional issue for in vivo analysis is that the activity of these human promoters is then regulated by murine transcription factors. Finally, core promoter diversity is a contributor to promoter activity and there may be combinatorial differences between the promoter sequences used and the original versus the viral core promoter. 37 Identifying transcriptional sequences that function well within the constraints of the hybrid LTR strategy is thus largely empirical. Nevertheless, this study has identified that a vector replacing the viral enhancer with ICAM-2 sequences, as an alternative to ppET-1, 26 is suitable for development. The latter has recently been used to drive TK expression in tumour vasculature with therapeutic benefit (Mavria et al, submitted for publication), demonstrating the potential utility of this approach. Extensive in vitro analysis of the ICAM-2 promoter fragment originally reported to function in transgenic mice 34 demonstrated the necessity (for transient activity in bovine endothelial cells) of two GATA-2 binding sites, an Sp1 site and an 8 bp palindrome (P 8 ). 38 The importance of four Ets sites conserved between mouse and human promoters has not been investigated. All of the aforementioned sites are present in the region incorporated into our vector. GATA-2 is involved in regulating several other endothelial cell-specific genes and P 8 is important for tie-2. 39 The presence of GATA-2 and Sp1, both of which are widespread, is clearly insufficient to generate specificity. This is reminiscent of the ppET-1 promoter, which requires binding sites for GATA-2 and AP-1 but for which endothelial specificity is likely provided by a factor such as Vzf1/DB1, a recently characterized endothelial cell-specific zinc-finger protein. 40 Greater understanding of the factors controlling expression specifically in endothelial cells will ultimately enable the design of an entirely synthetic promoter.
The variable dependence of LTR activity on the presence of the enhancer, in particular, has significance for transcriptional control using an alternative vector design, and in the context of the safety of retroviral vectors. Enhancer deletion has been used to generate self-inactivating vectors, 41 in which the expression cassette is entirely contained between the LTRs and transduction leads to the loss of LTR activity for avoidance of promoter interference. It is clear from our work that the efficacy of this inactivation is not equivalent in all cell types, potentially compromising the function of the internal (tissue-specific) promoter and/or allowing LTR-driven expression to continue. With regard to safety, it has recently become clear that LTR-driven expression of chromosomal genes at the sites of proviral integration led to leukaemia in at least two patients undergoing gene therapy for primary immunodeficiency using MLV-based vectors. 42 LTR modifications such as enhancer deletion could be envisaged as a preventive measure, but it will be necessary to demonstrate their effect in each of the cell targets at risk. Recent reports of replication-competent retroviruses with enhancer deletion underscore these concerns. 43 
Materials and methods
Cell lines
All cell lines were grown at 371C and 5% CO 2 in a humidified incubator. Human cell lines HT1080 (fibrosarcoma), A431 (epidermal carcinoma), 293 (transformed embryonic kidney epithelium), ECV304 (bladder carcinoma), KS Y-1 (Kaposi's sarcoma) 44 , TE671 (rhabdomyosarcoma) and EAhy926 (umbilical vein endothelial cells fused with A549 lung carcinoma cells) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. The PAE cell line (porcine aortic endothelium) and amphotropic retroviral packaging cell line TEFLY A8 (a TE671-based version of FLY A13, 45 a gift from F-L Cosset) were similarly maintained. The human endothelial cell lines HUVEC-C (spontaneously transformed umbilical vein endothelial cells) and HMEC-1 (transformed human dermal microvascular endothelium), 46 and a preparation of PBECs were maintained in Human microvascular endothelial growth Medium (Clonetics Corp., obtained from TCS Biologicals). PBECs (a gift from C Clarke and M O'Hare, University College London) were obtained by selection with the antibody Q-BEND/40 from reduction mammoplasty material and their nature confirmed by CD31 staining. They were used at passage 3.
Reverse transcription-PCR (RT-PCR)
Total RNA was extracted from cells at subconfluence using an RNeasy kit (Qiagen). RNA (1 mg) was reverse transcribed with oligo(dT) 15 primer using 20 U MoMLV reverse transcriptase in a 40 ml reaction, for 2 h at 421C. Denatured cDNA (5 ml) was used for PCR with primers designed to amplify over at least two exon junctions. For flt-1, 10% DMSO, 5% glycerol and 2.5 mM MgCl 2 were added and the primers 5 0 -CGAGAGGACGGACTCTGG 0 -CGGTAGAAG CACTTGTAGGC (amplifying þ 225 to þ 620) used with an annealing temperature of 601C; for the control glyceraldehyde-3-phosphate dehydrogenase (GapDH), the primers 5 0 -TGGATATTGTTGCGATCAATGCC and 5 0 -GATGGCATGGACTGTGGTCATG (amplifying þ 158 to þ 618) were used with an annealing temperature of 621C. PCR conditions were 35-40 cycles of 1 min at each of 961C, the annealing temperature and 721C.
Cloning of human promoter fragments
The following sequences, numbered relative to the transcription start site, were obtained from human genomic DNA using PCR: flt-1 (À805 to À34, EMBL:D6401632), ICAM-2 (À338 to À37, EMBL:M3233134) and KDR (À780 to À37, EMBL:X8977633). A 5 0 NheI site was incorporated in each case, as was a 3 0 SacI or XbaI site (indicated in bold type in the primers below), except for flt-1, for which the 3 0 -end was left blunt instead of adding an SacI site in order to maintain a putative Ets-1 transcription factor binding site next to the TATA box, since such sites have been implicated in tumour angiogenesis. 47 For flt-1, the forward primer 5 0 -AGAGCTAGCAGGAGCAGTTT CACGCC was used with 10% DMSO and either 5 0 -CTAGTTCTAGACTTTCCCCAGCCCACTTCCTACC and an annealing temperature of 631C or 5 0 -CTTTCCCCAGCCCACTTCC and 571C. For ICAM-2, the forward primer 5 0 -TCAGAGCTAGCCAGGCAT GACTCCAACAATG was used with either 5 0 -CTAGTTC TAGAAGCCTTCTGCAAACTGATGACTGCAT and an annealing temperature of 631C or 5 0 -TCAGAGAGCT CAGCCTTCTGCAAACTGATGAC and 581C. For KDR, the forward primer 5 0 -TCAGAGCTAGCCTCCTTCCCC TGGGCCTAAG was used with either 10% DMSO, 5 0 -CTAGTTCTAGAGAGGCGGGGCCATGCGGGGCGGG and an annealing temperature of 631C or 5 0 -TCAGA GAGCTCGAGGCGGGGCCATGCGGGG and 611C. PCR conditions were 30-35 cycles, of 1 min at each of 961C, the annealing temperature and 721C, using Pfu DNA polymerase. Products were digested and inserted into the MLV LTR of pDBN. 25 NheI/SacI was used for generating hybrid LTRs in the DEP backbone, with the exception of using an SacI site blunted with the Klenow fragment of DNA polymerase I for the flt-1 product, and NheI/XbaI was used for the DE backbone (see Figure 1c) . DNA sequencing was used to confirm the identity of the cloned fragments. The sequences obtained matched those published with the exception of a T to C change at À305 for KDR, and quadruple base repeats instead of triplets at À294 and À299 for ICAM-2 (as in a later publication Cowan et al 37 ) . These changes were authenticated in the source DNA.
Recombinant retroviral vectors
The plasmids pNeoMFGnlslacZ, used to generate the control unmodified vector, pDBN, containing the 3 0 LTR and used for constructing LTR-hybrids, and pDBN À (lacking the backbone multiple cloning site) have been described. 25 To delete the retroviral enhancer (DE), pDBN À was digested with NheI/XbaI and the 5.5 kb NheI fragment from pNeoMFGnlslacZ was inserted. To delete the retroviral proximal promoter (DP) or both regions (DEP), pDBN was digested with XbaI/SacI, or NheI/SacI, respectively, and the ends were blunted and self-ligated. The NheI-NotI fragments were then used to transfer these deletions into the 3 0 LTR in pNeoMFGnlslacZ after digestion with NheI(partial)/NotI. The NheINotI fragments of hybrid LTRs in pDBN were similarly used to transfer these modifications. The packaging cell line TEFLY A8 was used to generate recombinant retroviral vectors following calcium phosphate-mediated transfection of plasmid DNA. Stable transfectants (bulk populations or clones) were selected in 1 mg/ml G418. Virus was harvested from confluent monolayers and 0.45 mm filtered.
Analysis of vector performance
For determination of histochemical titre, target cells (seeded at 2.5 Â 10 4 cells/well in a 24-well plate the previous day) were infected in triplicate with serial dilutions of virus for 4 h in the presence of 8 mg/ml polybrene. The infected cells were grown to confluence, stained with 1 mg/ml 5-bromo-4-chloro-3-indolyl b-Dgalactopyranoside (X-Gal) and histochemical titres were determined from virus concentrations at which the infection titrated linearly. A quantitative photometric assay was used to determine b-galactosidase activity in cell lysates, as described. 48 To determine the proviral copy number in transduced TE671 cells, 10 mg of genomic DNA was digested with NheI or KpnI and analysed by Southern blotting, using a [a- 32 P]dCTPlabelled nlslacZ probe. Negative control DNA was loaded with plasmid to enable quantification of the proviral copy number after signals were measured using a Storm 860 phosphorimager system (Molecular Dynamics). The start site of transcripts driven from the 5 0 -LTR in transduced PAE cells was determined using a 5 0 /3 0 rapid amplification of cDNA ends (RACE) kit (Roche), as described. 25 Murine subcutaneous coinjection tumour models A 150 ml mix of 7.5 Â 10 6 X-irradiated (2000 rads) producer cells and 1.5 Â 10 6 KS Y-1 cells was injected subcutaneously into the flank of 4-to 6-week-old nu/ nu mice (Harlan). 26 Tumours were excised after 14-18 days, washed in PBS-A and fixed with 4% paraformaldehyde in TBS for 30 min at room temperature. After 20 min at room temperature in prestain (2 mM MgCl 2 , 0.01% sodium deoxycholate and 0.02% NP40 in PBS-A), the tumours were histochemically stained (prestain plus 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 and 1 mg/ml X-Gal) overnight at 371C. Stained tumours were washed in PBS-A and stored in 70% EtOH at 41C prior to paraffin embedding. Sections (10 mm) were cut, deparaffinized and counterstained with eosin. and to S Clinton for preparing the sections. In addition, we are grateful to F-L Cosset for providing the TEFLY A8 packaging cell line; RC Gallo for the KS Y-1 cell line; the Centers for Disease Control and Prevention, Atlanta for the HMEC-1 cell line; and C Clarke and M O'Hare for the primary breast microvascular endothelial cells.
